Revenue and profit growth driven by products transferred for sales
First written in FY2016-Q3. 23 of 32 entries say "Reframed", first in FY2017-Q1. Latest entry: 2026-05-12.
Fuji Pharma moved to the "Worse" side of this theme in 2018.
0 other companies' latest entry also says "Cited as achieved".
- 2026-05-12Cited as achievedEarnings
「Revenue for the interim consolidated accounting period was ¥29,716 million, up 23.3% year on year.」
The company has reported higher revenue across multiple areas, including women’s healthcare, biosimilars and the global CMO business. - FY2025-H1ReframedAnnual report
「Net sales for the cumulative interim consolidated period were ¥24,095 million, up 12.7% year on year. Women’s healthcare performed steadily, led mainly by Alissa Combination Tablets, a new treatment for dysmenorrhea launched in December 2024, Efmeno Capsules 100 mg and Favoir Tablets. In biosimilars, the company is focusing on Ustekinumab BS for subcutaneous injection 45 mg "F," a psoriasis treatment launched in May 2024, and is advancing efforts to further expand the biosimilars business by filing applications for manufacturing and marketing approval for 1 product in September 2024 and 2 products in October. In global CMO, contract revenue at OLIC increased. In other fields, growth in 2 products transferred from Mitsubishi Tanabe Pharma in July 2024 and 3 generic products launched in the previous fiscal year contributed mainly to sales.」
Net sales increased 12.7% year on year, with the growth profile shifting from one centered on products transferred from other companies to one supported by multiple sources of growth: women’s healthcare, biosimilars, global CMO, transferred products and generics. - FY2024-Q2WorsenedAnnual report
「In terms of profit, operating profit was ¥1,443 million, down 20.9% year on year, and ordinary profit was ¥2,165 million, down 11.8%. This reflected higher research and development expenses due to milestone payments to the licensor in connection with the FSN-013 filing and the payment for exclusive negotiating rights in Japan for the next-generation treatment for menopausal disorders being developed by U.S.-based Vistagen in Phase 2. Personnel expenses also increased because the company established a new specialized sales organization for the dermatology and gastrointestinal fields to market Ustekinumab BS for subcutaneous injection 45 mg, which was approved solely by the company and is scheduled for NHI price listing in May.」
Net sales increased, while expenses rose due to the milestone payment associated with the FSN-013 filing, the payment for exclusive negotiating rights to Vistagen products and the establishment of a specialized sales organization for Ustekinumab BS, resulting in lower operating profit and ordinary profit. - FY2024-Q1WorsenedAnnual report
「As a result, net sales for the cumulative first quarter of the consolidated fiscal year were ¥10,746 million, up 7.5% year on year. In terms of profit, the loss on sales of biologically derived products resulting from higher active pharmaceutical ingredient prices had been incorporated into the full-year sales plan, and the loss was recognized in full as an inventory write-down in the first quarter. Consequently, first-quarter gross profit was substantially below the same period of the previous year, but there was no impact on the full-year plan. In addition, selling, general and administrative expenses increased due to higher research and development expenses, including the acquisition of exclusive negotiating rights for PH80, a treatment for menopausal disorders, and license fees paid in connection with the filing for approval of FSN-013. As a result, the company reported an operating loss of ¥140 million, compared with operating profit of ¥1,190 million in the same quarter of the previous year, and an ordinary loss of ¥96 million, compared with ordinary profit of ¥1,579 million in the same quarter of the previous year. Meanwhile, profit attributable to owners of the parent was ¥2,739 million, up 145.8% year on year, due to the recognition of gains on sales of investment securities as extraordinary income.」
Net sales increased, but higher inventory write-downs associated with rising active pharmaceutical ingredient prices and higher research and development expenses resulted in an operating loss and an ordinary loss. Profit attributable to owners of the parent increased due to gains on sales of investment securities. - FY2023-Q3WorsenedAnnual report
「As a result, net sales for the cumulative third quarter of the consolidated fiscal year were ¥29,482 million, up 11.4% year on year. In terms of profit, operating profit was ¥2,403 million, down 33.5% year on year, due mainly to higher research and development expenses, while ordinary profit was ¥2,741 million, down 28.4%, and profit attributable to owners of the parent was ¥1,982 million, down 25.0%.」
Net sales increased 11.4%, while operating profit fell 33.5%, ordinary profit fell 28.4% and profit attributable to owners of the parent fell 25.0% due mainly to higher research and development expenses, continuing the pattern of higher revenue but lower profit from the previous quarter. - FY2023-Q2WorsenedAnnual report
「As a result, net sales for the cumulative second quarter of the consolidated fiscal year were ¥19,225 million, up 8.5% year on year. In terms of profit, operating profit was ¥1,824 million, down 32.7% year on year, due mainly to higher depreciation and amortization, while ordinary profit was ¥2,456 million, down 14.3%, and profit attributable to owners of the parent was ¥1,772 million, down 3.3%.」
Net sales increased 8.5%, while operating profit fell 32.7%, ordinary profit fell 14.3% and profit attributable to owners of the parent fell 3.3% due mainly to higher depreciation and amortization, resulting in another quarter of higher revenue but lower profit. - FY2023-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the consolidated fiscal year were ¥9,996 million, up 5.8% year on year. In terms of profit, operating profit was ¥1,190 million, down 23.8% year on year, due mainly to higher depreciation and amortization, while ordinary profit was ¥1,579 million, down 0.1%, and profit attributable to owners of the parent was ¥1,114 million, down 0.3%.」
The quarter shifted from the previous quarter’s trend of increases in both revenue and profit to a pattern of higher revenue but lower profit, with net sales up 5.8% while operating profit fell 23.8% due mainly to higher depreciation and amortization. - FY2022ReframedAnnual report
「As a result, net sales for the consolidated fiscal year were ¥35,426 million, up 4.2% year on year. In terms of profit, operating profit was ¥3,777 million, up 12.8%, ordinary profit was ¥3,725 million, up 14.6%, and profit attributable to owners of the parent was ¥2,696 million, up 10.9%, reflecting steady sales of products in the women’s healthcare field and growth in contract revenue at OLIC.」
Net sales, operating profit, ordinary profit and net profit increased further from the previous year’s increases in both revenue and profit, driven by sales of women’s healthcare products and growth in OLIC’s contract revenue. - FY2022-Q3ReframedAnnual report
「As a result, net sales for the cumulative third quarter of the current consolidated fiscal year were ¥26,470 million, up 3.8% year on year. Operating profit rose 0.3% to ¥3,612 million, ordinary profit rose 6.2% to ¥3,828 million, and net profit attributable to owners of the parent was unchanged year on year at ¥2,642 million.」
For the cumulative third quarter, net sales, operating profit and ordinary profit increased year on year, while net profit attributable to owners of the parent was flat year on year. The performance profile changed from higher operating and ordinary profit accompanied by lower net profit in the previous quarter. - FY2022-Q2ReframedAnnual report
「As a result, net sales for the cumulative second quarter of the current consolidated fiscal year were ¥17,726 million, up 2.6% year on year. On the earnings front, operating profit rose 1.0% to ¥2,712 million and ordinary profit rose 4.7% to ¥2,866 million, mainly because of lower R&D expenses. Net profit attributable to owners of the parent fell 9.3% to ¥1,834 million.」
Net sales, operating profit and ordinary profit increased year on year, while net profit attributable to owners of the parent declined. Lower R&D expenses were cited as a factor behind the increase in operating profit. - FY2022-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the current consolidated fiscal year were ¥9,446 million, up 1.6% year on year. The application of the revenue recognition accounting standard and related standards reduced reported net sales by ¥264 million compared with the previous accounting treatment. On the earnings front, operating profit fell 8.0% to ¥1,562 million, ordinary profit fell 8.7% to ¥1,581 million, and net profit attributable to owners of the parent fell 15.8% to ¥1,118 million, mainly because of higher R&D expenses and other factors.」
Compared with the revenue and earnings growth in the previous year, the current quarter showed net sales up 1.6% but declines in operating profit, ordinary profit and net profit, mainly because of higher R&D expenses and other factors. The disclosure also notes a ¥264 million reduction in reported net sales resulting from the application of the revenue recognition accounting standard. - FY2021ReframedAnnual report
「As a result, net sales for the current consolidated fiscal year were ¥33,990 million, up 0.6% year on year. Compared with the previous fiscal year, when Phase III trials for new drug development were concentrated, lower R&D expenses contributed to a 6.7% increase in operating profit to ¥3,349 million. Ordinary profit rose 9.0% to ¥3,250 million, and net profit attributable to owners of the parent rose 16.6% to ¥2,432 million.」
The performance profile shifted from lower revenue and earnings in the previous fiscal year to increases in net sales, operating profit, ordinary profit and net profit in the current fiscal year. Lower R&D expenses were cited as a factor behind the increase in operating profit. - FY2021-Q3RestatedAnnual report
「As a result, net sales for the cumulative third quarter of the current consolidated fiscal year were ¥25,498 million, up 2.4% year on year. On the earnings front, operating profit rose 62.0% to ¥3,600 million, ordinary profit rose 67.6% to ¥3,604 million, and net profit attributable to owners of the parent rose 68.8% to ¥2,641 million, mainly because of lower R&D expenses.」
Net sales and each profit measure increased year on year, and the disclosure continues to identify lower R&D expenses as a factor behind the increase in operating profit. - FY2021-Q2ReframedAnnual report
「As a result, net sales for the cumulative second quarter of the current consolidated fiscal year were ¥17,277 million, up 2.2% year on year. On the earnings front, operating profit rose 54.8% to ¥2,686 million, ordinary profit rose 70.0% to ¥2,738 million, and net profit attributable to owners of the parent rose 550.5% to ¥2,021 million, mainly because of lower R&D expenses.」
Performance shifted from the revenue and earnings decline in the previous year to revenue and earnings growth in the current quarter, with net sales up 2.2% and operating profit up 54.8%. Lower R&D expenses were cited as a factor behind profit growth. - FY2021-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the current consolidated fiscal year were ¥9,295 million, up 3.6% year on year. On the earnings front, operating profit rose 61.2% to ¥1,698 million, ordinary profit rose 59.6% to ¥1,732 million, and net profit attributable to owners of the parent rose 78.3% to ¥1,328 million, mainly because of lower R&D expenses.」
Performance shifted from the revenue and earnings decline in FY2020 to revenue and earnings growth in the current quarter, with net sales up 3.6% and operating profit up 61.2%. Lower R&D expenses were cited as a factor behind profit growth. - FY2020ReframedAnnual report
「Net sales for the current consolidated fiscal year were ¥33,793 million, down 6.9% year on year. On the earnings front, operating profit fell 24.8% to ¥3,139 million and ordinary profit fell 28.4% to ¥2,983 million, mainly because of the October 2019 and April 2020 drug price revisions and higher R&D expenses as new drug development progressed as scheduled. Net profit attributable to owners of the parent fell 29.6% to ¥2,085 million.」
For the full year, net sales, operating profit, ordinary profit and net profit attributable to owners of the parent all declined year on year. The disclosure cites the drug price revisions and higher R&D expenses associated with progress in new drug development as factors behind the earnings decline. - FY2020-Q3ReframedAnnual report
「As a result, net sales for the cumulative third quarter of the current consolidated fiscal year were ¥24,899 million, down 8.9% year on year. On the earnings front, operating profit fell 40.3% to ¥2,223 million and ordinary profit fell 42.1% to ¥2,151 million, mainly because of the October 2019 and April 2020 drug price revisions and higher R&D expenses as new drug development progressed as scheduled. Net profit attributable to owners of the parent fell 37.9% to ¥1,565 million.」
For the cumulative third quarter, net sales, operating profit, ordinary profit and net profit attributable to owners of the parent all declined year on year. The disclosure cites the drug price revisions and higher R&D expenses associated with progress in new drug development as factors behind the declines in revenue and earnings. - FY2020-Q2ReframedAnnual report
「As a result, net sales for the cumulative second quarter of the current consolidated fiscal year were ¥16,905 million, down 8.5% year on year. On the earnings front, operating profit fell 29.7% to ¥1,735 million and ordinary profit fell 35.6% to ¥1,610 million, mainly because of the October 2019 drug price revision and higher R&D expenses as new drug development progressed as scheduled. As a result of recognizing an impairment loss on investment securities classified as “other securities” whose fair value had declined significantly and was not expected to recover, net profit attributable to owners of the parent fell 81.7% to ¥310 million.」
Net sales fell 8.5% year on year, operating profit fell 29.7%, ordinary profit fell 35.6%, and net profit attributable to owners of the parent fell 81.7%. The disclosure identifies the drug price revision, higher R&D expenses and a ¥1,172 million valuation loss on investment securities as factors behind performance, making the revenue and earnings decline more concrete. - FY2020-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the current consolidated fiscal year were ¥8,968 million, down 12.7% year on year. On the earnings front, operating profit fell 34.4% to ¥1,053 million, ordinary profit fell 29.1% to ¥1,085 million, and net profit attributable to owners of the parent fell 32.0% to ¥745 million, mainly because of the October 2019 drug price revision and higher R&D expenses as new drug development progressed as scheduled.」
Net sales fell 12.7% year on year and operating profit fell 34.4%. In addition to the impact of the drug price revision, the disclosure cites higher R&D expenses associated with progress in new drug development as a factor behind the earnings decline, marking a shift from the previous performance profile centered on revenue growth, stable earnings or lower expenses to one involving declines in both revenue and earnings. - FY2019ReframedAnnual report
「Net sales for the current consolidated fiscal year were ¥36,279 million, down 4.3% year on year, a decrease of ¥1,629 million from the previous fiscal year. By product, sales of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 increased by ¥423 million and sales of the endometriosis treatment 「ジエノゲスト錠」 increased by ¥308 million, while sales of the nonionic contrast agent 「オプチレイ注」, whose marketing rights were transferred, fell by ¥1,452 million.」
For the full year, net sales declined, with the decrease resulting from the transfer of the marketing rights for 「オプチレイ注」 partly offset by higher sales of 「オイパロミン注」 and 「ジエノゲスト錠」. - FY2019-Q3ReframedAnnual report
「As a result, net sales for the cumulative third quarter of the current consolidated fiscal year were ¥27,324 million, down 2.0% year on year. On the earnings front, operating profit rose 5.0% to ¥3,726 million and ordinary profit rose 4.4% to ¥3,714 million, mainly because of lower selling, general and administrative expenses. Net profit attributable to owners of the parent fell 3.3% to ¥2,521 million.」
While net sales declined year on year, operating profit and ordinary profit increased because of lower selling, general and administrative expenses, while net profit attributable to owners of the parent declined. The disclosure describes a performance profile of higher operating and ordinary profit without revenue growth, alongside lower net profit. - FY2019-Q2ReframedAnnual report
「As a result, net sales for the cumulative second quarter of the current consolidated fiscal year were ¥18,483 million, up 2.9% year on year. On the earnings front, operating profit rose 8.4% to ¥2,467 million, mainly because of lower selling, general and administrative expenses. Ordinary profit rose 6.0% to ¥2,501 million, while net profit attributable to owners of the parent fell 2.7% to ¥1,695 million.」
Net sales, operating profit and ordinary profit increased year on year, while net profit attributable to owners of the parent declined. Lower selling, general and administrative expenses were identified as a factor behind the increase in operating profit, marking a change from the previous quarter's earnings decline caused by the drug price revision and higher expenses. - FY2019-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the current consolidated fiscal year were ¥10,279 million, up 3.2% year on year. On the earnings front, operating profit fell 7.0% to ¥1,605 million, ordinary profit fell 16.0% to ¥1,532 million, and net profit attributable to owners of the parent fell 15.8% to ¥1,096 million, mainly because of the impact of the April 2018 drug price revision and higher selling, general and administrative expenses.」
Although net sales increased, operating profit, ordinary profit and net profit attributable to owners of the parent all declined year on year. The disclosure explains that the drug price revision and higher selling, general and administrative expenses reduced earnings. - FY2018ReframedAnnual report
「Net sales for the current consolidated fiscal year were ¥37,909 million, up 7.1% year on year, an increase of ¥2,522 million from the previous fiscal year. Major contributors included a ¥752 million increase in sales of the macrocyclic MRI contrast agent 「マグネスコープ静注」, a ¥521 million increase in sales of the generic endometriosis treatment 「ジエノゲスト錠」, which was launched in June 2017, and a ¥270 million increase in sales of the nonionic contrast agent 「オプチレイ注」. Operating profit rose 1.8% to ¥4,391 million, resulting in revenue and earnings growth. Ordinary profit fell 3.4% to ¥4,472 million, while net profit attributable to the parent rose 2.2% to ¥3,372 million, a record high.」
Net sales rose 7.1%, accompanied by increases in individual product sales, and operating profit rose 1.8%, while ordinary profit fell 3.4%. Net profit attributable to the parent reached a record high, marking a change from the revenue decline and earnings decline described through the third quarter to the full-year performance. - FY2018-Q3ReframedAnnual report
「As a result, net sales for the cumulative third quarter of the current consolidated fiscal year were ¥27,872 million, up 7.1% year on year. Operating profit fell 0.4% to ¥3,547 million, ordinary profit fell 6.9% to ¥3,558 million, and net profit attributable to owners of the parent fell 3.0% to ¥2,606 million.」
While net sales increased, operating profit fell 0.4% year on year, ordinary profit fell 6.9%, and net profit attributable to owners of the parent fell 3.0%. Compared with the previous performance trend of revenue and earnings growth, the profile has shifted to revenue growth accompanied by lower earnings. - FY2018-Q2ReframedAnnual report
「As a result, net sales for the cumulative second quarter of the current consolidated fiscal year were ¥17,961 million, up 3.7% year on year. On the earnings front, despite higher R&D expenses, operating profit was essentially unchanged at ¥2,275 million, up 0.0%, due mainly to an improvement in the cost of sales. Ordinary profit fell 6.9% to ¥2,360 million, and net profit attributable to owners of the parent fell 2.6% to ¥1,743 million.」
Although net sales increased, operating profit was flat year on year, while ordinary profit and net profit attributable to owners of the parent declined. The disclosure cites higher R&D expenses and an improvement in the cost of sales, indicating a change in the earnings profile and in the explanation of the factors behind earnings growth seen through the previous quarter. - FY2018-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the current consolidated fiscal year were ¥9,957 million, up 11.5% year on year. On the earnings front, operating profit rose 35.4% to ¥1,725 million, mainly because of the timing shift in R&D expenses and an improvement in the cost of sales. Ordinary profit rose 19.9% to ¥1,824 million, and net profit attributable to owners of the parent rose 20.7% to ¥1,301 million.」
Revenue and earnings continued to grow, but the factors behind profit growth were described as a timing shift in R&D expenses and an improvement in the cost of sales, representing a change from the previous explanation centered on products transferred for marketing. - FY2017ReframedAnnual report
「Net sales were ¥35,387 million, up 3.4% year on year; operating profit was ¥4,314 million, up 20.9%; ordinary profit was ¥4,628 million, up 42.3%; and net profit attributable to owners of the parent was ¥3,301 million, up 55.8%, a record high.」
Describes revenue and earnings growth and record-high profit. The explanation of the factors behind revenue growth has shifted from a focus on products transferred for marketing to one that includes higher sales of products such as ウトロゲスタン, ジエノゲスト and ルナベル, as well as an improved cost ratio. - FY2017-Q3RestatedAnnual report
「As a result, net sales for the cumulative third quarter of the current consolidated fiscal year were ¥26,016 million, up 3.9% year on year. Operating profit was ¥3,561 million, up 24.8%; ordinary profit was ¥3,822 million, up 49.3%; and net profit attributable to owners of the parent was ¥2,688 million, up 61.4%.」
Revenue and earnings continued to grow over the cumulative third quarter. Unlike the previous quarter, this disclosure does not provide an explanation of specific factors behind profit growth. - FY2017-Q2RestatedAnnual report
「As a result, net sales for the cumulative second quarter of the current consolidated fiscal year were ¥17,324 million, up 2.9% year on year. On the earnings front, operating profit rose 25.0% to ¥2,274 million, mainly because of lower R&D expenses and an improved cost-of-sales ratio. Ordinary profit rose 46.9% to ¥2,535 million, mainly because foreign exchange gains arose on loans to subsidiaries. Net profit attributable to owners of the parent rose 66.8% to ¥1,789 million.」
The disclosure continues to describe year-on-year improvements in net sales and each profit measure, with lower R&D expenses, an improved cost-of-sales ratio and foreign exchange gains cited as factors behind profit growth. There is no substantive change from the previous quarter in the explanation of the factors behind revenue and earnings growth. - FY2017-Q1ReframedAnnual report
「As a result, net sales for the cumulative first quarter of the current consolidated fiscal year were ¥8,932 million, up 0.1% year on year. On the earnings front, operating profit rose 52.7% to ¥1,274 million, mainly because of lower R&D expenses and an improvement in the cost of sales. Ordinary profit rose 79.4% to ¥1,521 million, mainly because foreign exchange gains arose on loans to subsidiaries. Net profit attributable to owners of the parent rose 97.7% to ¥1,077 million.」
Unlike the previous disclosure, which identified contributions from products transferred for marketing as the main drivers of revenue and earnings growth, this disclosure describes limited sales growth and cites lower R&D expenses, an improved cost of sales and foreign exchange gains as factors behind the increase in profit. - FY2016-Q3First statedAnnual report
「Net sales were ¥25,028 million, up 8.8% year on year, mainly reflecting contributions from products transferred for marketing, including 「マグネスコープ静注」. Operating profit was ¥2,853 million, up 28.9%; ordinary profit was ¥2,559 million, up 15.6%; and net profit attributable to owners of the parent was ¥1,665 million, up 18.7%.」
Describes the results for the cumulative 3Q period and the contribution from products transferred for marketing.